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Abstract: Continuous positive airway pressure (CPAP) has been used in infants with bronchiolitis
for decades. Recently, high flow nasal cannula (HFNC) therapy was introduced We conducted
a retrospective study of treatment with CPAP vs. HFNC between 2013 and 2015, comparing the
development in respiratory rate, fraction of inspired oxygen (FiO2) and heart rate, treatment failure,
duration of treatment, and length of hospital stay. A sample size of 49 children were included.
Median age was 1.9 months. Median baseline pCO2 was 7.4 kPa in both groups, respiratory rate
per minute was 57 vs. 58 (CPAP vs. HFNC). Respiratory rate decreased faster in the CPAP group
(p < 0.05). FiO2 decreased in the CPAP group and increased in the HFNC group during the first
12 h, whereafter it decreased in both groups. (p < 0.01). Heart rate development was similar in both
groups. Twelve children (55%) changed systems from HFNC to CPAP due to disease progression.
There was no difference in length of treatment, hospital stay, or transmission to intensive care unit
between the groups. CPAP was more effective than HFNC in decreasing respiratory rate (RR) and
FiO2. No differences were observed in length of treatment or complications. Further studies should
be conducted to compare the efficacy of the two treatments of bronchiolitis, preferably through
prospective randomized trials.
Keywords: bronchiolitis; non-invasive ventilation; continuous positive airway pressure (CPAP); high
flow nasal cannula (HFNC); children
1. Introduction
Every winter, bronchiolitis due to respiratory syncytial virus (RSV) or other viruses is a common
cause of hospitalization in infants and young children. In Denmark, approximately 3% of children
under 2 years of age have been hospitalized due to RSV infection [1]. Clinically, bronchiolitis presents
with coughing, wheezing, retractions, mucus blocking of the airways, increased respiratory rate
and work, need of oxygen supply, and feeding difficulties. In some cases the condition proceeds to
respiratory failure and need for ventilatory support.
In Denmark, treatment with continuous positive airway pressure (CPAP) is standard for infants
with moderate-severe bronchiolitis and respiratory fatigue. The mechanism of CPAP is not fully
understood, but the positive pressure is thought to decrease the inspiratory resistance and thereby
relieve muscuar work and improve alveolar ventilation [2] It has been shown to abolish airway
occlusion and increase diaphragmatic tone [3] CPAP has been shown to be superior to standard care in
improving clinical outcomes and decreasing pCO2 [4,5]. However, evidence is scarce and two reviews,
among them a Cochrane review [6,7], have concluded that more randomized trials are needed in
evaluating the efficacy of CPAP in bronchiolitis.
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In the past decade, high flow nasal cannula (HFNC) therapy has been introduced as an alternative
method for the management of respiratory distress due to bronchiolitis. HFNC delivers a heated,
humidified airflow, and the FiO2 can be varied between 21% and 100% [8].
HFNC, like CPAP, is a high flow system and is able to generate a positive end expiratory pressure,
but unlike CPAP it does not have a valve [9]. HFNC is suggested to reduce the upper airway dead
space and resistance [10,11]. HFNC is considered a less invasive treatment than CPAP, better tolerated
by the patients, and easier to handle by the staff [12]. In some studies, HFNC has been shown to be
more efficient than standard care (e.g., CPAP) [12–14]. However, more evidence is needed to show the
efficacy of HFNC [15,16].
In the season of 2014–2015, HFNC was gradually introduced as an alternative method to CPAP at
the Pediatric Department of the Hospital of South West Jutland, Denmark. Prior to that, CPAP was the
primary choice for noninvasive respiratory support. We conducted a study of CPAP vs. HFNC in the
management of respiratory care in infants and young children with bronchiolitis, using data from the
seasons 2013–2014 and 2014–2015.
2. Materials and Methods
2.1. Settings and Patients
The Pediatric Department at the Hospital of South West Jutland is a broad pediatric department
which serves children and adolescents aged 0–17 years with pediatric and surgical conditions.
Semi-intensive care with CPAP/HFNC can be managed, and intubation/mechanical ventilation
can be initiated by the local intensive care unit, prior to transferal to the nearest Pediatric Intensive
Care Unit (PICU).
For the present study, bronchiolitis was defined as acute respiratory illness in children <2 years of
age, with characteristic patterns of wheeze, cough, and respiratory distress. Criteria for respiratory
support were, according to local guidelines, a clinical decision based on signs of respiratory failure:
high respiratory rate (RR), retractions, recurrent apnea, hypercapnia and acidosis.
Failure of treatment was assessed by a physician when the clinical response to the given treatment
was not sufficient. In case of failure, therapy could be changed to CPAP or mechanical ventilation,
and the child was eventually transferred to PICU. During CPAP/HFNC treatment, all children were
intensively observed by a trained nurse with heart rate (HR), RR, FiO2 and saturation scheduled
hourly. Blood tests including capillary gas values (pH, pCO2) were measured prior to treatment,
and controlled as needed.
Inclusion criteria were: children aged 0–2 years, with bronchiolitis, and need for non-invasive
respiratory support. The study period was from October 2013 to May 2015.
Exclusion criteria were: need of invasive respiratory support, monitoring in an intensive care unit
at time of admission, or a history of chronic respiratory disease.
The electronic patient journal system was searched for patients registries with ICD10 diagnose
codes DJ205, DJ210, DJ211, DJ219, DJ121 or procedure code BGFC32 in the winters of 2013–2014 and
2014–2015 to identify children fulfilling the inclusion criteria.
For CPAP, we used a binasal prong with a Benveniste valve (Dameca®, Copenhagen, Denmark)
connected to a humidifier (Fisher & Paykel Healthcare®, Auckland, New Zealand). According to our
guidelines, the initial flow was 14 L/min.
For HFNC, we used an Optiflow Junior (Fisher & Paykel Healthcare®, Auckland, New Zealand)
to deliver a heated, humidified flow. We used three sizes of nasal prongs, according to the weight
of the child. According to the guidelines from the manufacturer, the initial flow was 8 or 12 L/min,
corresponding the weight of the child.
Oxygen supply was delivered as needed to both systems to maintain a SpO2 above 92%.
Chest X-ray and nasopharyngeal mucus polymerase chain reaction (PCR) analysis for RSV and
metapneumovirus were routinely conducted in patients in need of respiratory support.
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2.2. Data Management
From patient journals, data regarding age, sex, prematurity, weight, RSV status, duration of
symptoms, device, blood gas analysis, treatment failure, duration of treatment, and length of hospital
stay were registered.
For this study, RR, FiO2 and HR were noted at treatment start time, and after 6, 12, 18, 24 and 48 h.
In case of a shift of device, the new device was noted from time of shift. In case of admission to PICU
(with or without invasive respiratory support) the case was noted as a failure, and data collection was
withdrawn from the time of failure.
2.3. Statistical Analysis
For group comparisons, Wilcoxon rank-sum test was used because data were generally not
normally distributed. Chi-squared test was used for binary outcomes.
Development in HR, RR and FiO2 was measured using a variance-components model with
maximum likelihood estimation. Device, time, age, and sex, as well as interaction between time and
device were chosen as explanatory variables. A squared link of time was also included to investigate
nonlinear effects. The model was fitted with significant variables using simple backward elimination.
Post-estimation analysis was conducted using residual diagnostics. For all analyses, significance level
was defined as p < 0.05.
All statistical analyses were performed using STATA version 10 statistical software (StataCorp,
College Station, TX, USA).
2.4. Ethical Approval
All procedures performed in studies involving human participants were in accordance with the
ethical standards of the institutional and national research committee and with the 1964 Helsinki
Declaration and its later amendments or comparable ethical standards. For this type of study, formal
consent is not required. Permission to gather patient journal information was given by the Danish
Health Authority (3-3013-1056/I/reference SMFS) according to the current legislation.
3. Results
Fourty-nine cases were reviewed and met the inclusion criteria. No cases were identified between
May 2014 and October 2014. During the two winter seasons between 2013 and 2015, 27 children
were treated with CPAP and 22 with HFNC. In the first period, all children were in CPAP; in the
second period 22 and 9 patients were treated by HFNC and CPAP, respectively. No differences were
observed in age, weight, gender, gestational age, or RSV status between the two groups (Table 1).
Symptom duration was reported one day longer at admission for the HFNC group, which was
peri-significant. Both groups were similar for X-ray description (±atelectasis), RR, HR, FiO2, and pCO2
at baseline (Table 1).
During the second season, where both systems were available, 31 children were included, of which
22 were treated with HFNC and 9 with CPAP. The CPAP children had a median age of 1.3 (0.6–1.9)
months vs. 2.2 (1.5–5.5) months in HFNC group, although the difference did not reach significance
(p = 0.07). There was no difference in the median baseline RR (56 (48–66) vs. 58 (50–60)) or pCO2
(7.2 (6.9–8.0) mmHg vs. 7.4 (5.6–8.0) mmHg) between the two groups included in the second season.
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Table 1. Descriptive statistics.
nCPAP HFNC p-value
n 27 22
Gender, boys n (%) 13 (48) 8 (36) ns
Age, months, median (IQ range) 1.7 (1.2–3.0) 2.2 (1.53–5.33) ns
Gestational age at birth, weeks + days, median
(IQ range) 39 + 3 (38 + 2–40 + 0) 40 (37 + 3–40 + 3) ns
Weight, kg, median (IQ range) 5.2 (3.9–6.6) 5.3 (4.7–6.7) ns
Symptom duration, days , median (IQ range) 4 (2–5) 5 (4–7) 0.052
RSV positive, n (%) 24 (89.9) 19 (90.5) ns
Atelectasis, n (%) 7 (30.4) 6 (33.3) ns
pCO2, kPa, median (IQ range) 7.4 (5.6–8.3) 7.4 (6–8.3) ns
Respiratory Rate per minute, median (IQ range) 57 (48–62) 58 (50–60) ns
FiO2, % (IQ range) 30 (21–35) 30 (25–35) ns
Pulse, per minute 156 (148–170) 161 (148–178) ns
IQ: Interquartile; nCPAP: Nasal continuous positive airway pressure; HFNC: High flow nasal cannula; RSV:
Respiratory syncytial virus; FiO2: fraction of inspired oxygen. Ns: non-significant.
No differences were observed in treatment length, hospitalization duration or transferal to PICU
(Table 2). More than half of the children from the HFNC group were changed to CPAP therapy
(p < 0.001). For patients experiencing system failure, median time from treatment start to change in
system was 18 h, whereas median time to referral to PICU were 31 h, with no difference between the
two groups. The four HFNC children which were transferred to PICU had all been changed to CPAP
prior to transferal, with a median time of 11.5 (5–25) h from change of system to transferal.
Table 2. Duration of treatment, hospital stay and system failure.
nCPAP HFNC p-value
Duration of treatment, median (hours) 93.5 (58.3–163.0) 93.0 (70–146) ns
Duration of hospitalization, median (days) 7 (4–10) 8 (5–11) ns
Device failure (shift to opposite), n (%) 0 (0%) 12 (55%) <0.001
Device failure (referral to PICU), n (%) 4 (15%) 5 (24%) ns
PICU: Pediatric Intensive Care Unit.
Using the variance-component model, we found that RR decreased over time in both groups.
It was found that the RR declined faster in the CPAP group (0 < 0.05), independently of age and
gender (Figure 1).
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Figure 1. Median respiratory rate (RR), FiO2 and heart rate (HR) during 48 h of treatment. RR and
FiO2 decreased significantly more in the CPAP group. HR decreased equally in both groups.
FiO2 declined over time in the CPAP group. In the HFNC group, FiO2 increased during the
first 12 h and reased for th rest of the treatme t (Figure 1). The difference in FiO2 development
between the groups was highly significant (p < 0.01). Age had a significant effect on FiO2, and was
thus kept in the model.
HR declined significantly with time in both groups (Figure 1). There was no difference between
systems, and no effect of any other explanatory variable.
4. Discussion
Our data suggest that CPAP was superior to HFNC with respect to reducing RR and need of oxygen
supply in infants with bronchiolitis. This is in opposition to Metge et al., who found no difference with
respect to RR developm nt [17]. On the contrary, Metge et al. found, in concordance with ur findings,
a higher FiO2 i the HFNC group, alt ough it did not reach significance. T e differe s may be
explained by differences in design and ma agement of outco es, as well as in pati nt population—the
children in our study being a few weeks older. In accordance with our findings, Milesi et al. recently
found a higher failure rate of HFNC compared to CPAP in treatment of infants with bronchiolitis [18].
In our study, more than half of the patients that started treatment with HFNC were changed to
CPAP treatment, suggesting a high level of treatment failure with HFNC. It should be remembered
that despite the diagnosis of system failure based on systematic observations of RR, respiratory work
and hypercapnia, there might have been a bias in the clinical decision towards favoring CPAP which is
the well-known treatment. On the contrary, as shown in Figure 1, both RR and FiO2 improved after
approximately 24 h, where many children were converted to CPAP treatment.
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The optimal pressure level of CPAP is 7 cm H2O. HFNC has been shown to be able to generate
a pressure of 4–5 cm H2O9. The actual positive end expiratory pressure (PEEP) of both systems is,
however, influenced by many factors e.g., whether the child is able to breath with a closed mouth and
to cooperate with the system. In HFNC, the available pressure also depends on the size and placement
of the nostril prongs, whereas CPAP, when placed correctly, is a hermetical system. We suggest that
our findings may be explained by CPAP’s better ability to keep an optimal and constant PEEP.
As mentioned earlier, in Denmark, CPAP is first line treatment for moderate-severe bronchiolitis,
in opposition to conservative treatment (oxygen, hydration etc.). However, even though a few studies
have shown that CPAP is superior to the conservative treatment, evidence is scarce. Only one
randomized study exists, a cross-over study comparing CPAP with standard care4. Our findings of
CPAP being superior to HFNC, with respect to lowering RR and FiO2, may contribute to the evidence
of CPAP in the management of bronchiolitis.
Our study is limited by its retrospective, unrandomized design. However, there was no difference
in age, gender, and disease severity, measured by pCO2, RR, pulse, and FiO2, at the inclusion time.
One might speculate that, during the second season, HFNC was chosen for the milder cases and CPAP
for the severe cases, but this was not the case, although there was a nonsignificant tendency of choosing
CPAP for the youngest children. We therefore conclude that the two groups were comparable with
respect to patient characteristics and disease severity. Further limitations of this study are the lack of
standardized measurements that could be planned in a prospective design (e.g., a standardized clinical
score and control pCO2). The limitations in this study emphasize the need of prospective randomized
trials comparing the effect of the two systems in treating bronchiolitis.
Even though our data showed the better effects of CPAP, HFNC may be a good alternative
for children with less severe bronchiolitis. Our study found no differences in treatment length,
hospitalization length, or referral to PICU, and indicates that HFNC is safe, if carefully monitored.
Future studies may be able to focus on subgroups of patients benefitting from the two systems.
5. Conclusions
CPAP was superior to HFNC in lowering RR and FiO2 in infants with bronchiolitis. More than
half of the children treated with HFNC were changed to CPAP treatment due to suspected treatment
failure. There were no differences between HFNC and CPAP in treatment length, hospitalization
length or transferal to PICU.
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